Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

[Status quo 5 years after the introduction of the new ISUP 2014/WHO 2016 prostate cancer grade groups].

Hupe MC, Offermann A, Sailer V, Merseburger AS, Perner S.

Aktuelle Urol. 2019 Dec;50(6):619-624. doi: 10.1055/a-0918-9473. Epub 2019 Aug 7. German.

PMID:
31390661
2.

Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.

Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.

Int J Cancer. 2020 Jan 15;146(2):577-588. doi: 10.1002/ijc.32551. Epub 2019 Jul 19.

PMID:
31271443
3.

TRIM24 as an independent prognostic biomarker for prostate cancer.

Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S.

Urol Oncol. 2019 Sep;37(9):576.e1-576.e10. doi: 10.1016/j.urolonc.2019.05.006. Epub 2019 Jun 7.

PMID:
31178279
4.

KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells.

Metzger E, Wang S, Urban S, Willmann D, Schmidt A, Offermann A, Allen A, Sum M, Obier N, Cottard F, Ulferts S, Preca BT, Hermann B, Maurer J, Greschik H, Hornung V, Einsle O, Perner S, Imhof A, Jung M, Schüle R.

Nat Struct Mol Biol. 2019 May;26(5):361-371. doi: 10.1038/s41594-019-0219-9. Epub 2019 May 6.

PMID:
31061526
5.

The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature.

Offermann A, Hupe MC, Sailer V, Merseburger AS, Perner S.

World J Urol. 2019 Apr 2. doi: 10.1007/s00345-019-02744-4. [Epub ahead of print] Review.

PMID:
30941561
6.

Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma.

Kümpers C, Jokic M, Haase O, Offermann A, Vogel W, Grätz V, Langan EA, Perner S, Terheyden P.

Front Med (Lausanne). 2019 Mar 13;6:27. doi: 10.3389/fmed.2019.00027. eCollection 2019.

7.

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A.

Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.

8.

[Influence of enhanced capacity for degradation of misfolded proteins on tumorigenesis].

Offermann A.

Pathologe. 2018 Sep;39(5):449-450. doi: 10.1007/s00292-018-0455-5. German. No abstract available.

PMID:
29971458
9.

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.

Klepsch V, Hermann-Kleiter N, Do-Dinh P, Jakic B, Offermann A, Efremova M, Sopper S, Rieder D, Krogsdam A, Gamerith G, Perner S, Tzankov A, Trajanoski Z, Wolf D, Baier G.

Nat Commun. 2018 Apr 18;9(1):1538. doi: 10.1038/s41467-018-04004-2.

10.

In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.

Krupar R, Schreiber C, Offermann A, Lengerke C, Sikora AG, Thorns C, Perner S.

Leuk Lymphoma. 2018 Oct;59(10):2493-2496. doi: 10.1080/10428194.2018.1434883. Epub 2018 Feb 12. No abstract available.

PMID:
29431550
11.

[Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].

Hupe MC, Offermann A, Perabo F, Chandhasin C, Perner S, Merseburger AS, Cronauer MV.

Urologe A. 2018 Feb;57(2):148-154. doi: 10.1007/s00120-017-0541-y. Review. German.

PMID:
29147733
12.

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.

Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.

13.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.

Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.

14.

Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer.

Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.

Clin Cancer Res. 2017 Apr 1;23(7):1829-1840. doi: 10.1158/1078-0432.CCR-16-0094. Epub 2016 Sep 27.

15.

Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner.

Jokić M, Vlašić I, Rinneburger M, Klümper N, Spiro J, Vogel W, Offermann A, Kümpers C, Fritz C, Schmitt A, Riabinska A, Wittersheim M, Michels S, Ozretić L, Florin A, Welcker D, Akyuz MD, Nowak M, Erkel M, Wolf J, Büttner R, Schumacher B, Thomale J, Persigehl T, Maintz D, Perner S, Reinhardt HC.

Mol Cancer Res. 2016 Nov;14(11):1110-1123. Epub 2016 Aug 11.

16.

The activation of OR51E1 causes growth suppression of human prostate cancer cells.

Maßberg D, Jovancevic N, Offermann A, Simon A, Baniahmad A, Perner S, Pungsrinont T, Luko K, Philippou S, Ubrig B, Heiland M, Weber L, Altmüller J, Becker C, Gisselmann G, Gelis L, Hatt H.

Oncotarget. 2016 Jul 26;7(30):48231-48249. doi: 10.18632/oncotarget.10197.

17.

Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.

Syring I, Klümper N, Offermann A, Braun M, Deng M, Boehm D, Queisser A, von Mässenhausen A, Brägelmann J, Vogel W, Schmidt D, Majores M, Schindler A, Kristiansen G, Müller SC, Ellinger J, Shaikhibrahim Z, Perner S.

Oncotarget. 2016 Apr 26;7(17):23043-55. doi: 10.18632/oncotarget.8469.

18.

MED15: a potential biomarker for head and neck squamous cell carcinoma?

Offermann A, Shaikhibrahim Z, Perner S.

Biomark Med. 2015;9(10):939-41. doi: 10.2217/bmm.15.57. Epub 2015 Oct 12. No abstract available.

19.

Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors.

Klümper N, Syring I, Offermann A, Shaikhibrahim Z, Vogel W, Müller SC, Ellinger J, Strauß A, Radzun HJ, Ströbel P, Brägelmann J, Perner S, Bremmer F.

Diagn Pathol. 2015 Sep 17;10:165. doi: 10.1186/s13000-015-0398-6.

20.

Clinical and molecular implications of MED15 in head and neck squamous cell carcinoma.

Shaikhibrahim Z, Offermann A, Halbach R, Vogel W, Braun M, Kristiansen G, Bootz F, Wenzel J, Mikut R, Lengerke C, Reischl M, Schröck A, Perner S.

Am J Pathol. 2015 Apr;185(4):1114-22. doi: 10.1016/j.ajpath.2014.12.010. Epub 2015 Mar 16.

PMID:
25791637
21.

MED12 overexpression is a frequent event in castration-resistant prostate cancer.

Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.

Endocr Relat Cancer. 2014 Aug;21(4):663-75. doi: 10.1530/ERC-14-0171. Epub 2014 Jun 17.

PMID:
24938407
22.

Words of wisdom: Re: Punctuated evolution of prostate cancer genomes.

Shaikhibrahim Z, Offermann A, Perner S.

Eur Urol. 2014 Mar;65(3):666-7. doi: 10.1016/j.eururo.2013.11.022. No abstract available.

PMID:
24484760
23.

MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.

Shaikhibrahim Z, Menon R, Braun M, Offermann A, Queisser A, Boehm D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O, Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S.

Int J Cancer. 2014 Jul 1;135(1):19-26. doi: 10.1002/ijc.28647. Epub 2013 Dec 9.

24.

Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.

Menon R, Deng M, Rüenauver K, Queisser A, Peifer M, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim Z, Perner S.

J Pathol. 2013 Dec;231(4):505-16. doi: 10.1002/path.4274. Erratum in: J Pathol. 2014 May;233(1):101. Pfeifer, Martin [corrected to Peifer, Martin].

PMID:
24114522
25.

Insulin receptors on isolated heart cells: effect of temperature and hydrolytic enzymes.

Eckel J, Offermann A, Reinauer H.

Basic Res Cardiol. 1982 May-Jun;77(3):323-32.

PMID:
7052057

Supplemental Content

Loading ...
Support Center